These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30919072)

  • 1. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
    Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
    Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
    Alvarez-Larrán A; Pereira A; Cervantes F; Arellano-Rodrigo E; Hernández-Boluda JC; Ferrer-Marín F; Angona A; Gómez M; Muiña B; Guillén H; Teruel A; Bellosillo B; Burgaleta C; Vicente V; Besses C
    Blood; 2012 Feb; 119(6):1363-9. PubMed ID: 22160617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance.
    Chiaranairungrot K; Kaewpreechawat K; Sajai C; Pagowong N; Sukarat N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L; Rattarittamrong E
    Hematology; 2022 Dec; 27(1):813-819. PubMed ID: 35894859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
    Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Clinical Outcomes Between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients.
    Lee SE; Hong J; Bang SM; Park J; Choi CW; Bae SH; Kim MK; Yoon SY; Kim SY
    J Korean Med Sci; 2024 Jan; 39(3):e24. PubMed ID: 38258361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
    Parasuraman SV; Shi N; Paranagama DC; Bonafede M
    J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
    Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
    Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can pegylated interferon improve the outcome of polycythemia vera patients?
    Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
    J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemia.
    Park YH; Lee S; Mun YC; Park DJ
    Cancer Med; 2023 Apr; 12(7):8073-8082. PubMed ID: 36622093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
    Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
    J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
    Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of polycythemia vera with hydroxyurea.
    Donovan PB; Kaplan ME; Goldberg JD; Tatarsky I; Najean Y; Silberstein EB; Knospe WH; Laszlo J; Mack K; Berk PD
    Am J Hematol; 1984; 17(4):329-34. PubMed ID: 6496458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
    Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
    Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
    Alvarez-Larrán A; Kerguelen A; Hernández-Boluda JC; Pérez-Encinas M; Ferrer-Marín F; Bárez A; Martínez-López J; Cuevas B; Mata MI; García-Gutiérrez V; Aragües P; Montesdeoca S; Burgaleta C; Caballero G; Hernández-Rivas JA; Durán MA; Gómez-Casares MT; Besses C;
    Br J Haematol; 2016 Mar; 172(5):786-93. PubMed ID: 26898196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
    Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
    J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.